---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-26-001071"
form_type: "8-K"
ticker: "IMUX"
cik: "0001280776"
company_name: "IMMUNIC, INC."
filed_at: "2026-08-11T11:05:36+00:00"
generated_at: "2026-08-11T11:10:25.254460+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Immunic Q2 2026 net loss $34.1M; ENSURE top-line data expected by year-end; Ridloff joins board

## Summary
- Q2 2026 net loss $34.1M ($0.80/share) vs $26.8M ($2.03/share) in Q2 2025; R&D spend $25.9M.
- Cash and equivalents $155.1M at June 30, 2026; expected to fund operations into late 2027.
- Phase 3 ENSURE relapsing MS top-line data expected by end of 2026; NDA submission mid-2027 if positive.
- Elena Ridloff appointed to Board Aug 6, 2026; received options for 50,740 shares.
- Daniel Vitt resigned from Board; separation agreement provides $670K lump sum, $276K bonus, 100% equity vesting.

## SEC filing metadata
- accession: 0001193805-26-001071
- form_type: 8-K
- ticker: IMUX
- cik: 0001280776
- company_name: IMMUNIC, INC.
- filed_at: 2026-08-11T11:05:36+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1280776/000119380526001071/0001193805-26-001071-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1280776/000119380526001071/e665684_8k-immunic.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-26-001071
- JSON: https://secwatch.observer/filing/0001193805-26-001071.json
- Plain text: https://secwatch.observer/filing/0001193805-26-001071.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.